

EXPORT LICENSE

NRC FORM 250
(10-07)

UNITED STATES OF AMERICA

Nuclear Regulatory Commission
Washington, D.C. 20555

NRC LICENSE NO.: XMAT422/02

Page 1 of 7

DOCKET NO.: 11005997

LICENSE EXPIRES: January 1, 2022

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.


<p>LICENSEE</p> <p>Cambridge Isotope Laboratories Inc. 50 Frontage Road Andover, MA 01810</p> <p>Attn: Gary Ionta</p>	<p>ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</p> <p>See pages 2 through 4</p>
<p>INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</p> <p>See pages 4 through 7</p>	<p>OTHER U.S. PARTY(IES) TO EXPORT</p> <p>None</p>
<p>APPLICANT'S REFERENCE NO.: Appl. Dated 12/12/2016</p> <p>QUANTITY(IES)</p>	<p>ULTIMATE DESTINATION(S): China</p> <p>DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)</p> <p>The license is amended to: 1) change the name and address of an ultimate consignee; 2) include additional intermediate and ultimate consignees; 3) remove several intermediate consignees; and 4) extend the date of expiration from April 30, 2017 to January 1, 2022.</p> <p>The licensee is authorized to export a cumulative total of 10,000 kilograms of deuterium in the form of deuterium gas, deuterium oxide, and deuterium compounds.</p> <p>All other conditions remain unchanged.</p>

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.

This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all of the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

THIS LICENSE IS INVALID UNLESS SIGNED BELOW
BY AUTHORIZED NRC REPRESENTATIVE

SIGNATURE:



NAME AND TITLE: Mugeh Afshar-Tous, Acting Deputy Director
Office of International Programs

DATE OF ISSUANCE: JUN 27 2017

EXPORT LICENSE

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): (Cont'd)

7. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

9. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): (Cont'd)

13. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

INTERMEDIATE FOREIGN CONSIGNEE(S):

1. [REDACTED]

(for distribution to ultimate consignees)

2. [REDACTED]

(for distribution to ultimate consignees)

3. [REDACTED]

(for distribution to ultimate consignees)

4. [REDACTED]

(for distribution to ultimate consignees)

INTERMEDIATE FOREIGN CONSIGNEE(S): (Cont'd)

5. [REDACTED]

(for distribution to ultimate consignees)

6. [REDACTED]

(for distribution to ultimate consignees)

7. [REDACTED]

(for distribution to ultimate consignees)

8. [REDACTED]

(for distribution to ultimate consignees)

9. [REDACTED]

(for distribution to ultimate consignees)

10. [REDACTED]

(for distribution to ultimate consignees)

INTERMEDIATE FOREIGN CONSIGNEE(S): (Cont'd)

11. [REDACTED]

(for distribution to ultimate consignees)

12. [REDACTED]

(for distribution to ultimate consignees)

13. [REDACTED]

(for distribution to ultimate consignees)

14. [REDACTED]

(for distribution to ultimate consignees)

15. [REDACTED]

(for distribution to ultimate consignees)

16. [REDACTED]

(for distribution to ultimate consignees)

INTERMEDIATE FOREIGN CONSIGNEE(S): (Cont'd)

17. [REDACTED]

(for distribution to ultimate consignees)

18. [REDACTED]

(for distribution to ultimate consignees)

19. [REDACTED]

(for distribution to ultimate consignees)

20. [REDACTED]

(for distribution to ultimate consignees)

21. [REDACTED]

(for distribution to ultimate consignees)

22. [REDACTED]

(for distribution to ultimate consignees)

//////////////////////////////////////END//////////////////////////////////////